Chuck Hansen
About Chuck Hansen
Chuck Hansen (age 68) serves as an independent director elected to the post‑combination board associated with Bannix Acquisition Corp.’s VisionWave transaction; shareholders approved his directorship unanimously at BNIX’s May 22, 2025 special meeting . He is a technology executive and inventor, Chairman & CEO of Electro Scan Inc. with 19 patents, and holds a BS from UC Berkeley and an MBA from UCLA . The combined company’s filings confirm Hansen’s independence under Nasdaq and SEC Rule 10A‑3 .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Electro Scan Inc. | Chairman & CEO | Not disclosed | Commercialization of cleantech pipeline diagnostics; holder of 19 patents |
| Hansen Analytics LLC | Founder & Chairman | Not disclosed | Analytics leadership; executive profile reference |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Crown Electrokinetics (CRKN) | Advisor | Not disclosed | Technology advisory |
| Moneta Ventures | Advisor | Not disclosed | Venture advisory |
Board Governance
- Current board seat: Elected as director in BNIX’s de‑SPAC to VisionWave; all 2,527,846 votes cast “FOR” at the May 22, 2025 special meeting .
- Independence: Board determined Hansen is independent under Nasdaq listing rules and SEC Rule 10A‑3 .
- Committees: Audit (member), Compensation (member), Nominating & Corporate Governance (member). Audit chaired by Haggai Ravid; Compensation and Nominating chaired by Eric T. Shuss .
- Attendance: Not disclosed in available BNIX or VisionWave filings; no meeting attendance rates reported .
Fixed Compensation
| Component | 2025 | Notes |
|---|---|---|
| Annual cash retainer (Director) | $36,000 | Payable quarterly under Independent Director Agreements |
| Committee chair fees | Audit Chair $10,000; Comp Chair $5,000; Gov Chair $5,000 | Hansen is a member (not chair); chair fees apply to designated chairs |
| Expense reimbursement | Reasonable expenses | Provided under agreements |
Performance Compensation
| Grant Type | Grant Date | Grant Value | Shares / Units | Vesting | Notes |
|---|---|---|---|---|---|
| Restricted Stock (Director equity) | 2025 | $60,000 | 5,245 shares (issued to Messrs. Shuss, Hansen, Ravid for 2025) | Vests in full after one year of service | Under 2024 Omnibus Equity Incentive Plan; per Independent Director Agreements |
Other Directorships & Interlocks
- BNIX/ VisionWave board: Hansen sits alongside Douglas Davis, Noam Kenig, Eric T. Shuss, and Haggai Ravid; composition adjusted to satisfy Nasdaq independence majority .
- Public company references: Bloomberg profile indicates VisionWave board member status . WSJ profile lists him as on Bannix’s board; cross‑reference aligns with BNIX’s de‑SPAC context .
Expertise & Qualifications
- Technical and IP: 19 patents; deep technology commercialization experience in cleantech diagnostics .
- Education: BS, University of California Berkeley; MBA, UCLA .
- Financial literacy: Board disclosures confirm Audit Committee comprised of financially literate independent directors .
Equity Ownership
- Director equity grants: 2025 restricted stock grant with $60,000 grant date fair value; issuance of 5,245 shares for service in 2025 to Messrs. Shuss, Hansen, and Ravid (per filing language) .
- Beneficial ownership totals, pledged shares, hedging: Not disclosed in available BNIX 2025 extension proxy or VisionWave 8‑K excerpts .
Governance Assessment
- Board effectiveness: Hansen’s inclusion across Audit, Compensation, and Nominating committees strengthens independent oversight; committee chairs held by other independents maintain checks and balances .
- Alignment: Cash retainer plus annual equity ($60k RS) provides at‑risk exposure via stock, with one‑year vesting that encourages near‑term alignment; longer‑dated PSUs not disclosed .
- Independence & conflicts: Filings explicitly classify Hansen as independent; no related‑party transactions tied to Hansen disclosed in BNIX/ VisionWave materials reviewed .
- RED FLAGS: None identified specific to Hansen. Broader listing/compliance risks for BNIX (Nasdaq deficiency notices and extensions) could affect overall governance stability, but are not director‑specific .
Notes
- BNIX’s Feb 21, 2025 DEF 14A is an extension proxy (special meeting), not a full annual proxy with director biographies; Hansen’s biography and compensation specifics are sourced from VisionWave’s post‑combination filings and investor materials, consistent with BNIX’s de‑SPAC structure .